tetano
Editor, Senior Moderator
Microbes Infect. 2017 Sep 9. pii: S1286-4579(17)30143-0. doi: 10.1016/j.micinf.2017.08.012. [Epub ahead of print]
[h=1]Single immunization with MF59-adjuvanted inactivated whole-virion H7N9 influenza vaccine provides early protection against H7N9 virus challenge in mice.[/h] Chang H[SUP]1[/SUP], Duan J[SUP]1[/SUP], Zhou P[SUP]1[/SUP], Su L[SUP]1[/SUP], Zheng D[SUP]2[/SUP], Zhang F[SUP]1[/SUP], Fang F[SUP]1[/SUP], Li X[SUP]1[/SUP], Chen Z[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] H7N9 influenza infection in humans would result in severe respiratory illness. Vaccination is the best way to prevent influenza virus. In this paper, we investigated the effect of early protection provided by inactivated whole-virion H7N9 influenza vaccine in a mouse model. Mice were immunized intramuscularly once with different doses of inactivated whole-virion H7N9 influenza vaccine alone or in combination with MF59 adjuvant. Specific IgM and IgG antibody titers in sera of mice were detected by ELISA 3, 5 and 7days after immunization. To evaluate the early protection provided by the vaccine, mice were challenged with lethal dose (40LD[SUB]50[/SUB]) of homologous virus 3, 5 and 7 days after immunization respectively. The survival rate and body weight change of mice during 21 days after challenge and the residual lung virus titer on 3[SUP]rd[/SUP] day after challenge were determined. The results demonstrated that mice could obtain effective protection 3 days after immunization with the vaccine at a high dose, and 5-7 days after immunization even at a low dose. Thus early immune responses induced by inactivated whole-virion H7N9 vaccine could provide effective protection.
Copyright ? 2017. Published by Elsevier Masson SAS.
[h=4]KEYWORDS:[/h] H7N9; MF59; adjuvant; early immune responses; influenza vaccine
PMID: 28899814 DOI: 10.1016/j.micinf.2017.08.012
[h=1]Single immunization with MF59-adjuvanted inactivated whole-virion H7N9 influenza vaccine provides early protection against H7N9 virus challenge in mice.[/h] Chang H[SUP]1[/SUP], Duan J[SUP]1[/SUP], Zhou P[SUP]1[/SUP], Su L[SUP]1[/SUP], Zheng D[SUP]2[/SUP], Zhang F[SUP]1[/SUP], Fang F[SUP]1[/SUP], Li X[SUP]1[/SUP], Chen Z[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] H7N9 influenza infection in humans would result in severe respiratory illness. Vaccination is the best way to prevent influenza virus. In this paper, we investigated the effect of early protection provided by inactivated whole-virion H7N9 influenza vaccine in a mouse model. Mice were immunized intramuscularly once with different doses of inactivated whole-virion H7N9 influenza vaccine alone or in combination with MF59 adjuvant. Specific IgM and IgG antibody titers in sera of mice were detected by ELISA 3, 5 and 7days after immunization. To evaluate the early protection provided by the vaccine, mice were challenged with lethal dose (40LD[SUB]50[/SUB]) of homologous virus 3, 5 and 7 days after immunization respectively. The survival rate and body weight change of mice during 21 days after challenge and the residual lung virus titer on 3[SUP]rd[/SUP] day after challenge were determined. The results demonstrated that mice could obtain effective protection 3 days after immunization with the vaccine at a high dose, and 5-7 days after immunization even at a low dose. Thus early immune responses induced by inactivated whole-virion H7N9 vaccine could provide effective protection.
Copyright ? 2017. Published by Elsevier Masson SAS.
[h=4]KEYWORDS:[/h] H7N9; MF59; adjuvant; early immune responses; influenza vaccine
PMID: 28899814 DOI: 10.1016/j.micinf.2017.08.012